Argenx Se · EURONEXT:ARGX
Argenx — Investor Presentation (August 2025)
26 slides from Argenx's investor presentation, August 2025
Slide 1: Reaching Patients Through Immunology Innovation
Reaching Patients Through Immunology Innovation C o r p o r a t e P r e s e n t a t i o n Au g u s t 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Innovation has no value unless it provides meaningful benefit to patients
Innovation has no value unless it provides meaningful benefit to patients 3
Slide 4: VYVGART is Setting a New Standard for Patients
VYVGART is Setting a New Standard for Patients MG1 CIDP Sustained Efficacy Meaningful ≥ 2 MG-ADL SCORE IMPROVEMENT IN 75% response PATIENTS DURING ECI STAGE A >75% OF VISITS Substantial No/minimal improvement in symptoms functional ability MSE = MG-ADL SCORE ≥2 POINT DECREASE IN Fred of 0 or 1 Jamil
Slide 5: Financial Strength to Invest in Sustainable Innovation
Financial Strength to Invest in Sustainable Innovation 1,000 949 Q2 2025 Product Net Sales Product Net Sales by Quarter $949M 900 790 800 737 700 600 573 Strong Cash* Position 478 $3.9B 500 398 374 $M 400 329 269 *Cash is an alternative performance measure (APM) and reflects cash, cash equivalents a
Slide 6: 2025 Strategic Priorities
2025 Strategic Priorities Reach more patients Expand next wave with VYVGART Fuel pipeline growth of innovation 10 Phase 3s 4 New PFS Launch Molecules in 10 Phase 2s Phase 1 6
Slide 7: Reach More Patients with VYVGART
Reach More Patients with VYVGART 7
Slide 8: Maximizing the VYVGART Opportunity
Maximizing the VYVGART Opportunity COMMERCIAL GROWTH DRIVERS Pre-Filled Syringe Supporting Earlier Line Use Presentation Global Expansion CIDP gMG Patient Activation Label Expansion Geography 8
Slide 9: Strong Launch Fundamentals Driving Expansion
Strong Launch Fundamentals Driving Expansion MG PATIENT GROWTH CIDP PATIENT GROWTH #1 Branded Consistent QoQ Biologic for gMG US New Patient Starts Reaching Patients Earlier Continued Launch Momentum PRESCRIBER EXPANSION BROADEST OFFERING 1K PFS Increased Patient Prescribers 15% new to VYVGART Deman
Slide 10: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG Path to 60K Addressable Patients U.S. Addressable MG Patients +25K +7K 60K Growth in Biologics +11K Share of Market Ocular 17K Seronegative PFS Driving Expansion Addressable Total Addressable Market at Launch Market in 2030 Source: argenx market research 10
Slide 11: Opportunity To Set New Standard in Ocular MG
Opportunity To Set New Standard in Ocular MG Ocular Domain Effect in ADAPT (1) Addressing Unmet Need High Disease Burden Impaired ability to work, drive and participate in social activities MG-ADL ocular subdomain %change from baseline in High Treatment Burden Frequent chronic, high doses of oral co
Slide 12: Delivering Impact for CIDP Patients
Delivering Impact for CIDP Patients 2,500 CIDP Patients treated globally Scott, CIDP Patient 12
Slide 13: Reaching Patients Across the Globe
Reaching Patients Across the Globe DECISIONS PENDING FOR 2025 US EU • VYVGART Hytrulo PFS • PFS launched in gMG gMG approved for self-injection in • CIDP launched with first patients in Saudi Arabia gMG and CIDP Germany Japan • CIDP launched with positive early feedback DECISIONS PENDING FOR 2025 VY
Slide 14: Fuel Pipeline Growth
Fuel Pipeline Growth aa argenx?
Slide 15: Our Pipeline is Positioned to Fuel Continuous Growth
Neuromuscular Our Pipeline is GBS Positioned to Fuel MG Crisis NMOSD Rheumatology Continuous Growth MG Steroid IMNM Taper oMG SJD snMG AIE MMN SSC Bubble Size and Color Indicates CIDP CIDP DM ASyS Prevalence Lead gMG SMA Expand CMS ITP DM ALS <15k 15-100k 100-300k Investigate/ESR DGF LN TED Asset IT
Slide 16: Empasiprubart is Now a Phase 3 Asset
Empasiprubart is Now a Phase 3 Asset Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity Complement C2-Specific Empasiprubart Factor C2 Antibody IgG IgM Mannose sugar CP LP MMN and CIDP C4 C2 Registrational Studies C3 C5 DGF and DM Proof of Concept Stu
Slide 17: Phase 2 ARDA Study: Transformational Data in MMN
Phase 2 ARDA Study: Transformational Data in MMN Empasiprubart Treated Patients Feel Significant Unmet Need Study Met Primary Endpoint Better than their Best on IVIg Life-Limiting Symptoms Empasiprubart reduced risk Cohort 1: 94.4% improved of IVIg retreatment by up to 100 91% Percentage of Particip
Slide 18: Disrupting Blockbuster Markets
Disrupting Blockbuster Markets Two Head-to-Head Phase 3 Studies with IVIg Innovation Builds Markets Following similar analogues in MG and MS MMN EMPASSION Study Ongoing More innovation brings better >400 patients enrolled in iMMersioN outcomes for more natural history study patients CIDP Future EMVI
Slide 19: ARGX-119 is Now a Phase 3 Asset
ARGX-119 is Now a Phase 3 Asset Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity MuSK MuSK Agonist ARGX-119 Antibody CMS Registrational Study ALS Proof-of-concept Study MuSK P P SMA Proof-of-concept Study Crucial for Neuromuscular SIMPLE Junction Fu
Slide 20: Expand Next Wave of Innovation
Expand Next Wave of Innovation 20
Slide 21: 4 Phase 1 Molecules in 2025
4 Phase 1 Molecules in 2025 Continued Leadership with Broad Immune System Targets ARGX-213 ARGX-121 ARGX-109 ARGX-220 FcRn IgA IL-6 Target Undisclosed Fc-ABDEGTM Fc-ABDEGTM NHance® α-albumin VHH Prolonged IgG reduction Rapid, deep IgA reduction Best-in-class potency First-in-class sweeper Potential
Slide 22: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline Active IIP Programs 4 PHASE 1 10 Proof of Concept 10 PHASE 3 APPROVED Neuro Target Neuro Target ARGX-213 (FcRn) Lupus Nephritis Seronegative MG Neuro Target Neuro Target ARGX-109 (IL6) AMR Ocular MG Neuro Target Rheum Target ARGX-121 (IgA) Scleroderma
Slide 23: Significant Milestones through 2026
Significant Milestones through 2026 1H25 PFS approval (FDA, EMA) CHMP CIDP Positive Recommendation Regional PFS Approvals PFS Canada, Japan decisions on approval Efgartigimod IVIg Switch CIDP Ph4 DECISIONS ON APPROVAL Efgartigimod Seronegative MG Ph3 2H25 Efgartigimod Lupus Nephritis Ph2 Empasipruba
Slide 24: Strong Growth Trajectory to 50K Patients
Strong Growth Trajectory to 50K Patients 50K CMS DM CIDP Sjogren’s Myositis TED MMN oMG snMG CIDP ITP gMG Wave 1: TODAY Wave 2 (2026-2027) Wave 3 (2028-2030) VYVGART Empasiprubart ARGX-119 24
Slide 25: Vision 2030
Vision 2030 COMMITMENT TO OUR INNOVATION MISSION 5 New Molecules in Phase 3 10 Labeled Indications 50k Patients on Treatment 25
Slide 26: Alternative Performance Measure
Alternative Performance Measure In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for the company’